Mon. 29 Jan 2024, 8:29am ET
Benzinga
Biotech, News, General
Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion
72% Reduction in All-Cause Mortality and 52% Reduction in Primary Major MAEs when Compared to Current Standard of Care Hemi-arch Procedure